

Decitabine combined regimen in the therapy of Blastic plasmacytoid dendritic cell neoplasm: case report

Jun Guan¹, Ying Zhou¹, xia Mao², Liang Zou¹, and Hui Cheng¹

¹Wuhan No 1 Hospital

²Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology

December 12, 2021

Abstract

We enrolled a patient diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN) . We have found that TET2, KRAS and BRAF may be involved in the development of the disease, and the combination therapy of Decitabine (DAC) and Arsenic acid (ASO) may be effective for BPDCN harboring the TET2 mutations.

Hosted file

20211201BPDCN.doc available at <https://authorea.com/users/450729/articles/549023-decitabine-combined-regimen-in-the-therapy-of-blastic-plasmacytoid-dendritic-cell-neoplasm-case-report>



